Market Place
Sourcing Support
BioLineRx to Present Motixafortide Data for Sickle Cell at ASH 2024
05 Nov 2024 //
PR NEWSWIRE
Almac Pharma Services Supports Rapid Launch of BioLineRx’s APHEXDA motixafortide
18 Jun 2024 //
PRESS RELEASE
BioLineRx Announces Clinical Trial Pact With St Jude`s For Motixafortide
30 May 2024 //
PR NEWSWIRE
BioLineRx presents economic model data for APHEXDA® at ISPOR 2024
06 May 2024 //
PR NEWSWIRE
BioLineRx Presents Apheresis Center Efficiency Data on APHEXDA®
17 Apr 2024 //
PR NEWSWIRE
BioLineRx Strengthens Intellectual Property Estate
04 Mar 2024 //
PR NEWSWIRE
BioLineRx Announces First Patient Dosed in Ph 2 Trial Evaluating Motixafortide
28 Feb 2024 //
PR NEWSWIRE
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA
16 Feb 2024 //
PR NEWSWIRE
BioLineRx Announces First Patient Dosed in Ph 1 Trial Evaluating Motixafortide
21 Dec 2023 //
PR NEWSWIRE
BioLineRx Entered Agreement with Motixafortide in Asia, Advised by MSQ Ventures
31 Oct 2023 //
PR NEWSWIRE
BioLineRx Announces Data from Phase 2 Clinical Trial with Motixafortide
28 Sep 2023 //
PR NEWSWIRE
BioLineRx Announces Acceptance of Presentation on Ph 2 Trial with Motixafortide
19 Sep 2023 //
PR NEWSWIRE
BioLineRx Announces FDA Approval of APHEXDA for Hematopoietic Stem Cells
11 Sep 2023 //
PR NEWSWIRE
BioLineRx Announces Initiation of Phase 2 Trial in First Line Metastatic Pancreatic Cancer
17 Jul 2023 //
PR NEWSWIRE
BioLineRx Announces Publication in Nature Medicine of its GENESIS Ph3 Trial
17 Apr 2023 //
PR NEWSWIRE
BioLineRx Announces Collaboration with Washington University School of Medicine
06 Mar 2023 //
PR NEWSWIRE
BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA
10 Nov 2022 //
PRNEWSWIRE
BioLineRx to Present on Cost-Effectiveness of Motixafortide in Myeloma
03 Nov 2022 //
PRNEWSWIRE
BioLineRx Announces U.S. Commercialization Plan for APHEXDA
27 Sep 2022 //
PRNEWSWIRE
BioLineRx Announces Submission of NDA to FDA for Motixafortide
12 Sep 2022 //
PRNEWSWIRE
BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics in PDAC
28 Jun 2022 //
PRNEWSWIRE
BioLineRx Announces Successful Completion of Pre-NDA Meeting for Motixafortide
18 Jan 2022 //
PRNEWSWIRE
BioLineRx Reports Q3 2021 Financial Results and Provides Corporate Update
18 Nov 2021 //
PRNEWSWIRE
BioLineRx shares rise 8% after Motixafortide study results
13 Oct 2021 //
SEEKINGALPHA
BioLineRx Announces Final Results from Phase 2a COMBAT/KEYNOTE-202
16 Dec 2020 //
PRNEWSWIRE
BioLineRx Announces Final Results from Phase 2a COMBAT/KEYNOTE-202
16 Dec 2020 //
PRNEWSWIRE
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3
30 Oct 2020 //
BIOSPACE
BioLineRx Announces Positive Results from Ph 3 Trial of Motixafortide
30 Oct 2020 //
PRNEWSWIRE
BioLineRx Announces Notice of Allowance from USPTO Patent Covering Motixafortide
27 Feb 2020 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.